tetano
Editor, Senior Moderator
J Clin Med
. 2022 Dec 10;11(24):7342.
doi: 10.3390/jcm11247342.
The Course of COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases
Marta Rorat[SUP] 1 [/SUP], Dorota Zarębska-Michaluk[SUP] 2 [/SUP], Justyna Kowalska[SUP] 3 [/SUP], Krzysztof Kujawa[SUP] 4 [/SUP], Magdalena Rogalska[SUP] 5 [/SUP], Dorota Kozielewicz[SUP] 6 [/SUP], Beata Lorenc[SUP] 7 [/SUP], Katarzyna Sikorska[SUP] 8 9 [/SUP], Piotr Czupryna[SUP] 10 [/SUP], Beata Bolewska[SUP] 11 [/SUP], Jadwiga Maciukajć[SUP] 12 [/SUP], Tomasz Piekoś[SUP] 13 [/SUP], Regina Podlasin[SUP] 14 [/SUP], Anna Dworzańska[SUP] 15 [/SUP], Włodzimierz Mazur[SUP] 16 [/SUP], Michał Brzdęk[SUP] 2 [/SUP], Anna Szymanek-Pasternak[SUP] 17 [/SUP], Robert Flisiak[SUP] 5 [/SUP]
Affiliations
Abstract
Patients with systemic autoimmune rheumatic disease (SARD) have increased susceptibility to viral infections, including SARS-CoV-2. The aim of this study was to analyse the SARD patient population with COVID-19 (coronavirus disease 2019) in terms of baseline characteristics, severity, course and outcomes of the disease compared with the non-SARD group, and to identify factors associated with prognosis, including remdesivir therapy efficacy. Retrospective study comprised 8220 COVID-19 cases from the SARSTer database, including 185 with SARD. Length of hospitalisation, duration of oxygen therapy, mortality and the need for HFNO (high-flow nasal oxygen) and/or NIV (noninvasive ventilation) were significantly higher in the SARD versus non-SARD group. There was no difference in clinical features on admission to hospital. Patients with SARD were older and more likely to have cardiovascular, pulmonary and chronic kidney diseases. Age, the presence of cardiovascular disease, more severe conditions on admission and higher inflammatory marker values were found to be risk factors for death in the SARD group. In patients with SARD treated with remdesivir, there was a trend towards improved mortality but without statistical significance. Length of hospitalisation, 28-day mortality and the need for HFNO and/or NIV were higher in the SARD group. These patients often had other chronic diseases and were older.
Keywords: connective tissue diseases; immunodeficiency; remdesivir; respiratory failure.
. 2022 Dec 10;11(24):7342.
doi: 10.3390/jcm11247342.
The Course of COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases
Marta Rorat[SUP] 1 [/SUP], Dorota Zarębska-Michaluk[SUP] 2 [/SUP], Justyna Kowalska[SUP] 3 [/SUP], Krzysztof Kujawa[SUP] 4 [/SUP], Magdalena Rogalska[SUP] 5 [/SUP], Dorota Kozielewicz[SUP] 6 [/SUP], Beata Lorenc[SUP] 7 [/SUP], Katarzyna Sikorska[SUP] 8 9 [/SUP], Piotr Czupryna[SUP] 10 [/SUP], Beata Bolewska[SUP] 11 [/SUP], Jadwiga Maciukajć[SUP] 12 [/SUP], Tomasz Piekoś[SUP] 13 [/SUP], Regina Podlasin[SUP] 14 [/SUP], Anna Dworzańska[SUP] 15 [/SUP], Włodzimierz Mazur[SUP] 16 [/SUP], Michał Brzdęk[SUP] 2 [/SUP], Anna Szymanek-Pasternak[SUP] 17 [/SUP], Robert Flisiak[SUP] 5 [/SUP]
Affiliations
- PMID: 36555957
- DOI: 10.3390/jcm11247342
Abstract
Patients with systemic autoimmune rheumatic disease (SARD) have increased susceptibility to viral infections, including SARS-CoV-2. The aim of this study was to analyse the SARD patient population with COVID-19 (coronavirus disease 2019) in terms of baseline characteristics, severity, course and outcomes of the disease compared with the non-SARD group, and to identify factors associated with prognosis, including remdesivir therapy efficacy. Retrospective study comprised 8220 COVID-19 cases from the SARSTer database, including 185 with SARD. Length of hospitalisation, duration of oxygen therapy, mortality and the need for HFNO (high-flow nasal oxygen) and/or NIV (noninvasive ventilation) were significantly higher in the SARD versus non-SARD group. There was no difference in clinical features on admission to hospital. Patients with SARD were older and more likely to have cardiovascular, pulmonary and chronic kidney diseases. Age, the presence of cardiovascular disease, more severe conditions on admission and higher inflammatory marker values were found to be risk factors for death in the SARD group. In patients with SARD treated with remdesivir, there was a trend towards improved mortality but without statistical significance. Length of hospitalisation, 28-day mortality and the need for HFNO and/or NIV were higher in the SARD group. These patients often had other chronic diseases and were older.
Keywords: connective tissue diseases; immunodeficiency; remdesivir; respiratory failure.